Vifor Pharma AG Logo

Vifor Pharma AG

A global leader in specialty pharmaceuticals for iron deficiency and nephrology.

VIFN | SW

Overview

Corporate Details

ISIN(s):
CH0364749348
LEI:
529900KO6CN2D9OE1F19
Country:
Switzerland
Address:
Rechenstrasse 37, 9014 St. Gallen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CSL Vifor is a global specialty pharmaceuticals company and a leader in iron deficiency and nephrology therapies. As a pioneer in iron-based treatments, the company develops, manufactures, and markets innovative products for iron deficiency anemia and related conditions in areas including heart failure, gastroenterology, and women's health. In partnership with its joint company, Vifor Fresenius Medical Care Renal Pharma, CSL Vifor is expanding its presence in nephrology, committed to launching therapies that address the full spectrum of kidney disease. The company specializes in strategic global partnering, in-licensing, and marketing pharmaceutical products to serve patients with unmet medical needs in over 100 countries.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Vifor Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vifor Pharma AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vifor Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-03-09 N/A Executive member Sell None 4,335,210.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,951,125.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,851,300.00 CHF
2022-03-09 N/A Executive member Sell None 1,535,160.00 CHF
2022-03-09 N/A Non-Executive member Sell None 1,450,515.00 CHF
2022-03-09 N/A Executive member Sell None 920,205.00 CHF
2022-03-09 N/A Executive member Sell None 530,310.00 CHF
2022-03-09 N/A Non-Executive member Sell None 382,140.00 CHF
2022-03-09 N/A Non-Executive member Sell None 330,495.00 CHF
2022-03-09 N/A Executive member Sell None 287,925.00 CHF

Peer Companies

Company Country Ticker View
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden RESP
REYON PHARMACEUTICAL CO., LTD Logo
Develops & makes APIs, generics, cell/gene therapies, and offers biopharma CDMO services.
South Korea 102460
Roche Holding AG Logo
A global leader in pharmaceuticals and diagnostics, pioneering personalized healthcare solutions.
Switzerland RO
ROHTO PHARMACEUTICAL CO.,LTD. Logo
Manufactures OTC drugs, skincare, and cosmetics with a focus on eye and dermatological health.
Japan 4527
RPbio Inc. Logo
A global CDMO specializing in soft capsules, pharmaceuticals, and health functional foods.
South Korea 314140
Develops and produces IVD kits and biological pharmaceuticals for the healthcare sector.
Türkiye RTALB
SAMIL PHARMACEUTICAL CO.,LTD Logo
Develops & manufactures drugs for eye & liver diseases, with a broad portfolio & CDMO services.
South Korea 000520
SAMJIN PHARMACEUTICAL CO.,LTD Logo
Researches & develops drugs for cardiovascular, respiratory, and gastrointestinal disorders.
South Korea 005500
SAMSUNG BIOLOGICS CO.,LTD. Logo
A CDMO providing end-to-end development and manufacturing services for the biopharma industry.
South Korea 207940
SanBio Company Limited Logo
Developing regenerative cell therapies for severe neurological disorders like brain injury and stroke.
Japan 4592

Talk to a Data Expert

Have a question? We'll get back to you promptly.